CHD5与KLF5蛋白在胃癌组织中的表达及其与预后的关系

表1 CHD5和KLF5在胃癌中的表达及其与病理特征关系

临床病理特征	n	CHD5				KLF5
		-	+	χ2值	P 值	-	+	χ2值	P值
年龄
<50岁	70	43(61.4%)	27(38.6%)	4.350	0.037	39(55.7%)	31(44.3%)	1.512	0.219
≥50岁	138	104(75.4%)	34(24.6%)			89(64.5%)	49(35.5%)
性别
男	121	84(69.4%)	37(30.6%)	0.219	0.640	76(62.8%)	45(37.2%)	0.198	0.657
女	87	63(72.4%)	24(27.6%)			52(59.8%)	35(40.2%)
肿瘤部位
胃近端	14	12(85.7%)	2(14.3%)	1.773	0.412	11(78.6%)	3(21.4%)	2.707	0.258
胃体部	86	61(70.9%)	25(29.1%)			55(64.0%)	31(36.0%)
胃远端	108	74(68.5%)	34(31.5%)			62(57.4%)	46(42.6%)
瘤体大小
<5 cm	102	72(70.6%)	30(29.4%)	0.001	0.979	64(62.7%)	38(37.3%)	0.123	0.726
≥5 cm	106	75(70.8%)	31(29.2%)			64(60.4%)	42(39.6%)
组织类型
乳头状腺癌	8	4(50%)	4(50%)	5.816	0.121	4(50%)	4(50%)	5.412	0.144
管状腺癌	129	86(66.7%)	43(33.3%)			73(56.6%)	56(43.4%)
黏液腺癌	45	36(80.0%)	9(20.0%)			31(68.9%)	14(31.1%)
印戒细胞癌	26	21(80.8%)	5(19.2%)			20(76.9%)	6(23.1%)
分化程度
高分化	13	7(53.8%)	6(46.2%)	11.534	0.003	5(38.5%)	8(61.5%)	16.771	<0.0001
中分化	63	36(57.1%)	27(42.9%)			28(44.4%)	35(55.6%)
低分化	128	102(79.69%)	26(20.31%)			92(71.9%)	36(28.1%)
未分化	4	2(50%)	2(50%)			3(75.0%)	1(25.0%)
组织侵犯
T1+T2	60	22(36.7%)	38(63.3%)	56.533	<0.0001	25(41.7%)	35(58.3%)	59.885	<0.0001
T3+T4	148	125(84.5%)	23(15.5%)			126(85.1%)	22(14.9%)
区域淋巴转移
N0	103	44(42.7%)	59(57.3%)	77.018	<0.0001	32(31.1%)	71(68.9%)	80.185	<0.0001
N1	32	31(96.9%)	1(3.1%)			30(93.8%)	2(6.2%)
N2	40	39(97.5%)	1(2.5%)			36(90.0%)	4(10.0%)
N3	33	33(100%)	0(0%)			30(90.9%)	3(9.1%)
远处转移
M0	177	118(66.7%)	59(33.3%)	9.197	0.002	99(55.9%)	78(44.1%)	15.771	<0.0001
M1	31	29(93.5%)	2(6.5%)			29(93.5%)	2(6.5%)
TNM 分期
I+II	117	59(50.43%)	58(49.57%)	85.545	<0.0001	50(42.74%)	67(57.26%)	63.239	<0.0001
III+IV	91	88(96.7%)	3(3.3%)			78(85.71%)	13(14.29%)

表2 影响胃癌患者预后的多因素分析 (Cox比例风险回归模型)

危险因素	P值	OR值	95% CI
性别	0.003	1.609	1.176-2.200
肿瘤部位	0.019	1.365	1.051-1.773
组织分化	0.019	0.723	0.550-0.949
远处转移	<0.0001	4.946	2.273-10.762
TNM分期	<0.0001	2.631	1.787-3.873
CHD5	<0.0001	0.248	0.134-0.456
KLF5	<0.0001	0.372	0.227-0.608